Major Depressive Disorder

A new cohort study confirmed a previously reported association between treatment with antidepressants and hip fracture in older adults, but it contained a twist.


Use the links here to see all of our coverage of sessions, speakers, and posters at Psych Congress 2018.

Adding mirtazapine to a serotonin-noradrenaline reuptake inhibitor or selective serotonin reuptake inhibitor for treatment-resistant depression is no more effective than adding placebo, according to a study.

When added to an antidepressant, combination buprenorphine-samidorphan (ALKS 5461) was safe and effective in easing depressive symptoms in patients with major depressive disorder who had an inadequate response to an antidepressant alone, according to a pair of phase 3 trials.

Patients with major depressive disorder (MDD) treated with the anticonvulsant ezogabine demonstrated a significant drop in depressive symptoms and an increase in resilience in a small trial described online in Molecular Psychiatry.

Cognitive behavioral humanistic and interpersonal training (CATCH-IT) may be better than health education as a primary care intervention to reduce risk in adolescents with subsyndromal depression, researchers say.



Psychedelic compounds are powerful, and they have great potential to help patients with intractable conditions. Yet any compound with that kind of power also has the potential to harm, and that harm should not be trivialized.

This year at orientation, there was a huge elephant in the room.

Perhaps patients would benefit if they had some concrete saying, a mantra as it were, to remind themselves outside the therapy room of key lessons.



Alex Kopelowicz, MD; Ross A. Baker, PhD, MBA; Cathy Zhao, PhD, MS, BS; Raymond Sanchez, MD; Margaretta Nyilas, MD; Claudette Brewer, BA; Erica Lawson; Timothy Peters-Strickland, MD
Andrew Valadez, BS; Rustin Berlow, MD
Martha Sajatovic, MD; Andrew Cutler, MD; Khodayar Farahmand, PharmD; Joshua Burke, MS; Scott Siegert, PharmD; Grace Liang, MD
Faisal Kagadkar, MBBS; Shanila Taha, MBBS; Venkatesh Sreeram, MBBS



Psych Congress Steering Committee members Vladimir Maletic, MD, MS, and Jon W. Draud, MD, MS, discuss established and emerging treatment options for patients with mixed mood states.

Dr. Murrough discusses new research regarding a novel approach for depression management.

Vladimir Maletic, MD, MS, discusses factors that influence a patient's response to treatment and advances in pharmacologic strategies.